April 2016 in “Journal of Investigative Dermatology” This study found that the peptide derivative beta-Ala-Pro-Dab-NHbenzyl may reduce wrinkles and sebum production in human skin by inhibiting dipeptidyl peptidase 4, suggesting potential for acne and skin inflammation treatment.
2 citations
,
November 2020 in “Der Hautarzt” This case report suggests an association between the use of Sitagliptin, a DPP-4 inhibitor, and the development of alopecia universalis in a diabetic patient.
7 citations
,
September 2019 in “European Journal of Case Reports in Internal Medicine” This case report describes a 68-year-old man who developed both alopecia areata and bullous pemphigoid after starting linagliptin for diabetes, suggesting a possible link with DPP-4 inhibitors.
4 citations
,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.
April 2021 in “Journal of Investigative Dermatology” Blocking DPP4 can help prevent fat loss and skin fibrosis.
April 2021 in “Journal of Investigative Dermatology” This study found that skin bacteria promote regeneration in wound-induced hair follicle neogenesis, suggesting a role for IL-1β signaling and challenging the belief that infection inhibits healing.
April 2019 in “Journal of Investigative Dermatology” This study found that DPP4 is significantly involved in matrix deposition and fibrosis in human skin fibroblasts, although the exact functions of DPP4 remain unclear.
May 2023 in “Journal of Investigative Dermatology” In this study, researchers found that topical application of the diabetes medication Sitagliptin in mice accelerates hair follicle regeneration and reduces fibrosis, suggesting it could be repurposed to treat hair loss conditions like alopecia.
4 citations
,
November 2024 in “International Journal of Biological Macromolecules” In this study, the researchers developed a cellulose nanofiber-based scaffold containing sitagliptin and zinc sulfide nanoparticles, which promoted scarless healing and hair follicle regeneration in rats by targeting DPP4+ fibroblasts, suggesting a novel approach for improved wound healing and skin regeneration.
February 2025 in “Journal of Neonatal Surgery” This study explores the role of antidiabetic medications, particularly metformin, GLP-1 receptor agonists, and DPP-4 inhibitors, in managing PCOS, highlighting their combination with hormonal therapies and lifestyle interventions for a comprehensive treatment approach.
April 2018 in “Journal of Investigative Dermatology” In this animal study, the researchers found that DPP4 plays a crucial role in scar formation and wound-induced hair follicle neogenesis in mice, impacting regenerative repair.
14 citations
,
July 2021 in “Reviews in endocrine and metabolic disorders” This study explores how SARS-CoV-2 interacts with endocrine organs and highlights specific endocrine molecules that help explain the progression and outcomes of COVID-19, especially in patients with certain metabolic conditions.
This review investigates the relationship between polycystic ovarian syndrome and the development of type 2 diabetes mellitus but reports no new clinical findings.
20 citations
,
December 2017 in “Cardiovascular diabetology” This study found that the DPP-4 inhibitor linagliptin slowed the progression of premature aging characteristics in klotho-/- mice, including improved body weight, cognitive function, and hair retention.
11 citations
,
January 2015 in “Dermatology” This study found multiple factors, both inherited and acquired, that may lead to bradykinin-mediated angio-oedema, proposing a new classification based on bradykinin production and catabolism imbalance.
1 citations
,
January 2024 in “NPJ breast cancer” This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.
August 2019 in “Journal of Invertebrate Pathology” This study observed that different alkaline buffers had a significant impact on the volume of liquid consumed by fall armyworm larvae, emphasizing the importance of measuring imbibed volumes to reduce dose errors in bioassays.
6 citations
,
December 2022 in “Frontiers in Pharmacology” This review examines the potential therapeutic effects and mechanisms of quercetin for treating polycystic ovary syndrome, noting improved clinical parameters in some studies but presenting no new results.
April 2016 in “Journal of Investigative Dermatology” This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.
April 2019 in “Journal of Investigative Dermatology” This study found that mice lacking REDD1 experienced an expansion of dermal white adipose tissue through both hypertrophy and hyperplasia, suggesting a potential therapeutic target for skin adipogenesis regulation.
1 citations
,
February 2025 in “South Asian Research Journal of Pharmaceutical Sciences” This study used in-silico molecular docking to evaluate the antidiabetic potential of Eclipta alba leaf flavonoids, finding that compounds like apigenin, syringic acid, and vanillic acid effectively bind to the target protein aldose reductase, suggesting a promising inhibitory action.
19 citations
,
July 2018 in “Medicines” This review highlights the pharmaceutical potential of secondary metabolites from Juniperus species, noting promising antitumor, antibacterial, and antiviral activities, but reports no new experimental findings.
34 citations
,
September 2020 in “BMC Endocrine Disorders” This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” This review examines existing research and clinical trials on the use of dupilumab for various skin, respiratory, and gastrointestinal disorders, but it reports no new clinical findings.
65 citations
,
February 2009 in “The journal of investigative dermatology/Journal of investigative dermatology” This paper discusses the hypothesis that anti-acne agents may work by reducing FGFR2 signaling, and emphasizes FGFR2's potential role in acne pathogenesis, but it reports no new experimental findings.
8 citations
,
June 2022 in “Frontiers in bioengineering and biotechnology” This study found that a collagen patch made with fibroblast-derived extracellular matrix (fdECM) extracted from human lung fibroblasts enhanced wound healing by promoting wound contraction, angiogenesis, and skin remodeling in full-thickness skin wound models, including those with diabetic ulcers.
26 citations
,
January 2017 in “Acta dermato-venereologica” This review examines the use of monoaminergic antidepressants for inflammatory skin disorders and reports they may reduce dermatological symptoms, suggesting a potential role beyond treating psychiatric conditions.
7 citations
,
August 2025 in “European Journal of Endocrinology” The authors concluded that incorporating routine endocrinology consultations into transplant care could address CNI-related endocrine toxicities, but prospective studies are needed to assess the impact on graft and patient survival.
In this study using a virtual screening approach, eriocitrin and silymarin were identified as potent flavonoid compounds that strongly and stably interacted with 5α-reductase type II, suggesting potential development as novel treatments for androgenic alopecia.
April 2019 in “Journal of Investigative Dermatology” This study found that CYP11A1-derived vitamin D3 analogs inhibit fibroblast proliferation and decrease collagen production through VDR expression, showing potential antifibrotic and antiproliferative activity in human dermal fibroblasts.